B+
Bull case
25%
Probability
Target price
$48.00
+45.5% vs current
VTVT
vTv TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$31.00
-6.1% vs current
B-
Bear case
25%
Probability
Target price
$18.00
-45.5% vs current
AI sentiment snapshot
Latest data as of 2026-04-28
Recent news sentiment (30D)
+55.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+45.7
Score
AI commentary
Primary-source support is solid for the basic facts, but the investable thesis remains a cautious monitoring view because external coverage is thin, recent news flow in the packet is limited to a March 10, 2026 earnings snapshot, and the deterministic prior is only neutral with relatively high uncertainty. Social coverage was not provided, so sentiment confidence should not be upgraded on narrative alone.
RankAlpha Sentiment Codex - 2026-04-28
Open full AI memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-01-30eventBalance-sheet de-risking from 2025 financing and Newsoara upfront paymentHigh impact
vTv reported about $88.9 million of cash at December 31, 2025, about $80.0 million of gross proceeds from the 2025 private placement, and a January 30, 2026 Newsoara amendment tied to a $20.0 million upfront payment that expanded HPP737 rights globally, which materially improved near-term runway but does not remove later funding risk [#10-K-2026-03-10].
2026-09-30catalystCATT1 Phase 3 enrollment completion remains the main value inflectionHigh impact
The core thesis is still cadisegliatin execution: vTv says the Phase 3 CATT1 trial resumed in May 2025, continues enrolling, and is expected to complete enrollment in the third quarter of 2026; the same filing says the company expects funding well past CATT1 topline data [#10-K-2026-03-10].
2026-12-31catalystAdditional cadisegliatin study starts could add supporting evidence but are secondary to CATT1High impact
Management disclosed supportive cadisegliatin work including a thorough QT study and a Phase 2 study in type 1 diabetes patients using hybrid closed loop insulin infusion systems expected to start in 2026, plus a partner-funded 300-patient Middle East Phase 2 study in insulin-dependent type 2 diabetes expected to begin screening in 2026; these are useful supporting markers but are not the primary valuation driver versus CATT1 [#10-K-2026-03-10] [#8-K-2026-03-10].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-28 • Updated nightlySource: Internal modelMethodology